MTEM Stock Overview
A clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Molecular Templates, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.37 |
| 52 Week High | US$5.37 |
| 52 Week Low | US$0.29 |
| Beta | 1.22 |
| 11 Month Change | -38.33% |
| 3 Month Change | -75.58% |
| 1 Year Change | -92.53% |
| 33 Year Change | -99.38% |
| 5 Year Change | -99.79% |
| Change since IPO | -99.59% |
Recent News & Updates
There's No Escaping Molecular Templates, Inc.'s (NASDAQ:MTEM) Muted Revenues Despite A 30% Share Price Rise
Oct 10
Earnings Release: Here's Why Analysts Cut Their Molecular Templates, Inc. (NASDAQ:MTEM) Price Target To US$18.00
Aug 17Recent updates
There's No Escaping Molecular Templates, Inc.'s (NASDAQ:MTEM) Muted Revenues Despite A 30% Share Price Rise
Oct 10Earnings Release: Here's Why Analysts Cut Their Molecular Templates, Inc. (NASDAQ:MTEM) Price Target To US$18.00
Aug 17Molecular Templates, Inc.'s (NASDAQ:MTEM) Shares Bounce 27% But Its Business Still Trails The Industry
Jul 30Little Excitement Around Molecular Templates, Inc.'s (NASDAQ:MTEM) Revenues As Shares Take 48% Pounding
Apr 03Lacklustre Performance Is Driving Molecular Templates, Inc.'s (NASDAQ:MTEM) 26% Price Drop
Dec 20There's No Escaping Molecular Templates, Inc.'s (NASDAQ:MTEM) Muted Revenues Despite A 45% Share Price Rise
Apr 17What Does The Future Hold For Molecular Templates, Inc. (NASDAQ:MTEM)? These Analysts Have Been Cutting Their Estimates
Nov 16Time To Worry? Analysts Are Downgrading Their Molecular Templates, Inc. (NASDAQ:MTEM) Outlook
Aug 14Molecular Templates GAAP EPS of -$0.44 misses by $0.01, revenue of $4.42M misses by $2.6M
Aug 11Rock star Growth Puts Molecular Templates (NASDAQ:MTEM) In A Position To Use Debt
Apr 29Health Check: How Prudently Does Molecular Templates (NASDAQ:MTEM) Use Debt?
Dec 30Some Analysts Just Cut Their Molecular Templates, Inc. (NASDAQ:MTEM) Estimates
Nov 25Is Molecular Templates (NASDAQ:MTEM) Using Debt In A Risky Way?
Sep 22News Flash: Analysts Just Made A Notable Upgrade To Their Molecular Templates, Inc. (NASDAQ:MTEM) Forecasts
Aug 15Need To Know: Analysts Just Made A Substantial Cut To Their Molecular Templates, Inc. (NASDAQ:MTEM) Estimates
May 18Brokers Are Upgrading Their Views On Molecular Templates, Inc. (NASDAQ:MTEM) With These New Forecasts
Mar 21Need To Know: The Consensus Just Cut Its Molecular Templates, Inc. (NASDAQ:MTEM) Estimates For 2021
Feb 21Is Molecular Templates (NASDAQ:MTEM) A Risky Investment?
Jan 26
Shareholder Returns
| MTEM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.3% | 4.0% | 2.0% |
| 1Y | -92.5% | 18.0% | 32.4% |
Return vs Industry: MTEM underperformed the US Biotechs industry which returned 18.3% over the past year.
Return vs Market: MTEM underperformed the US Market which returned 32.6% over the past year.
Price Volatility
| MTEM volatility | |
|---|---|
| MTEM Average Weekly Movement | 63.8% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MTEM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MTEM's weekly volatility has increased from 34% to 64% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 62 | Eric Poma | www.mtem.com |
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors.
Molecular Templates, Inc. Fundamentals Summary
| MTEM fundamental statistics | |
|---|---|
| Market cap | US$2.64m |
| Earnings (TTM) | -US$15.63m |
| Revenue (TTM) | US$25.47m |
0.1x
P/S Ratio-0.2x
P/E RatioIs MTEM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MTEM income statement (TTM) | |
|---|---|
| Revenue | US$25.47m |
| Cost of Revenue | US$29.23m |
| Gross Profit | -US$3.76m |
| Other Expenses | US$11.87m |
| Earnings | -US$15.63m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.37 |
| Gross Margin | -14.75% |
| Net Profit Margin | -61.35% |
| Debt/Equity Ratio | 0% |
How did MTEM perform over the long term?
See historical performance and comparison